Treatment interruption during concurrent chemoradiotherapy of uterine cervical cancer; analysis of factors and outcomes
- PMID: 25081681
- DOI: 10.7314/apjcp.2014.15.14.5653
Treatment interruption during concurrent chemoradiotherapy of uterine cervical cancer; analysis of factors and outcomes
Abstract
Background: To evaluate factors which effect treatment interruption during concurrent chemoradiotherapy (CCRT) and overall survival in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital.
Materials and methods: Between January 2006 and December 2007, 107 patients with stage IB2-IVA as FIGO staging, 2000, were treated with CCRT in Srinagarind Hospital. Factors which caused treatment interruptions and impacted on overall survival were reviewed and analyzed.
Results: Twenty of 107 patients had treatment interruption during CCRT in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital. The causes of treatment interruption were as follows: hematologic toxicity was found in 16 of 20 cases, 12 cases with grade 2 and 4 cases with grade 3; three of 20 cases had gastrointestinal toxicities, 1 case with grade 2 and 2 cases with grade 3; one case had grade 3 skin toxicity. The mean total treatment time of the uninterrupted and interrupted groups were significantly different (78.98 days vs 161.80 days, p <0.001). The patients who could tolerate ≥5 cycles of cisplatin administration had significantly higher mean white blood counts (WBC) (9,769 cells/ mm3 vs 7,141 cells/mm3, p=0.02). The mean initial hemoglobin (Hb) in the uninterrupted group was significantly higher than the interrupted group (11.5 mg% vs 10.3 mg%, p=0.03). Other factors including age, KPS, initial platelets, initial serum creatinine levels showed no statistical significance. The 3-year overall survival of the uninterrupted group was better than in the interrupted group (78.6% vs 55.0%, p=0.03).
Conclusions: The initial Hb and WBC levels were significantly correlated with treatment interruption during CCRT in patients with uterine cervical cancer. The 3-year overall survival of the uninterrupted group was significantly better than interrupted group. These factors may then be used indirectly to predict the outcomes of treatment.
Similar articles
-
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.J Gynecol Oncol. 2017 Jan;28(1):e15. doi: 10.3802/jgo.2017.28.e15. J Gynecol Oncol. 2017. PMID: 27958682 Free PMC article.
-
[Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].Zhonghua Fu Chan Ke Za Zhi. 2013 Oct;48(10):763-7. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24406134 Chinese.
-
Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial.Asian Pac J Cancer Prev. 2010;11(1):201-7. Asian Pac J Cancer Prev. 2010. PMID: 20593957 Clinical Trial.
-
[Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].Zhonghua Fu Chan Ke Za Zhi. 2015 Feb;50(2):125-30. Zhonghua Fu Chan Ke Za Zhi. 2015. PMID: 25877610 Chinese.
-
Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.J Radiat Res. 2015 Mar;56(2):305-14. doi: 10.1093/jrr/rru101. Epub 2014 Nov 26. J Radiat Res. 2015. PMID: 25428244 Free PMC article.
Cited by
-
Assessment of the prevalence of pain, adequacy of pain management and influencing factors in patients undergoing radiotherapy.Ecancermedicalscience. 2022 Dec 2;16:1483. doi: 10.3332/ecancer.2022.1483. eCollection 2022. Ecancermedicalscience. 2022. PMID: 36819795 Free PMC article.
-
Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer.J Gastrointest Oncol. 2022 Feb;13(1):185-196. doi: 10.21037/jgo-21-482. J Gastrointest Oncol. 2022. PMID: 35284138 Free PMC article.
-
The incidence and risk factors of acute radiation-induced dermatitis in gynecologic malignancies treated with intensity-modulated radiation therapy.Transl Cancer Res. 2020 Oct;9(10):6062-6069. doi: 10.21037/tcr-20-796. Transl Cancer Res. 2020. PMID: 35117217 Free PMC article.
-
Impact of COVID-19 on Outcomes for Patients With Cervical Cancer in India.JCO Glob Oncol. 2021 May;7:716-725. doi: 10.1200/GO.20.00654. JCO Glob Oncol. 2021. PMID: 33999708 Free PMC article.
-
Acute chemoradiotherapy toxicity in cervical cancer patients.Open Med (Wars). 2020 Sep 2;15(1):822-832. doi: 10.1515/med-2020-0222. eCollection 2020. Open Med (Wars). 2020. PMID: 33336040 Free PMC article.